Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Trial Profile

A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SRF 231 (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Surface Oncology
  • Most Recent Events

    • 18 Dec 2018 Results presented in a Surface Oncology media release.
    • 18 Dec 2018 According to a Surface Oncology media release, to date, 18 patients have been treated with SRF231 on an every-three-week schedule. An additional SRF231 data is expected in second half on 2019.
    • 29 May 2018 According to a Surface Oncology media release, initial clinical results from this trial are expected in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top